All In Biotech

Drug Trial Radar · NCT02446912

Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Jan 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

460

Actual

Start

Jun 9, 2015

Primary completion

Jul 17, 2018

Study completion Jul 17, 2018

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
PRA Health Sciences
First posted
May 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

Conditions

  • Active Systemic Lupus Erythematosus

Interventions

  • AnifrolumabBiological

    Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses

  • PlaceboDrug

    Placebo IV administration every 4 weeks from Week 0 to Week 48

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)Time frame: Week 52

Locations

145 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    El Cajon, California

  • Research Site

    La Jolla, California

  • Research Site

    Los Alamitos, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Aventura, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Plantation, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Vero Beach, Florida

  • Research Site

    Decatur, Georgia

  • Research Site

    Lawrenceville, Georgia

  • Research Site

    Marietta, Georgia

  • Research Site

    Boise, Idaho

  • Research Site

    Idaho Falls, Idaho

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Hagerstown, Maryland

  • Research Site

    Hagerstown, Maryland

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Nashua, New Hampshire

  • Research Site

    Freehold, New Jersey

  • Research Site

    Great Neck, New York

  • Research Site

    New Hyde Park, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Middleburg Heights, Ohio

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Tulsa, Oklahoma

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Wyomissing, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Charleston, South Carolina

Showing 40 of 145 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.